Advertisement

Topics

Mylan cuts forecasts on delays in new drugs, weak prices

10:16 EDT 9 Aug 2017 | Reuters

(Reuters) - Mylan NV said on Wednesday that delays in launching key new drugs and eroding prices for generics in the United States will hurt its profitability this year and in 2018, sending its shares down more than 6 percent.

Original Article: Mylan cuts forecasts on delays in new drugs, weak prices

NEXT ARTICLE

More From BioPortfolio on "Mylan cuts forecasts on delays in new drugs, weak prices"

Quick Search
Advertisement